Heparin Léčiva (Heparin Sodium)

Heparin Léčiva is employed in clinical practice to address several thrombotic conditions. It is indicated for patients who require anticoagulation therapy in various settings.

• Prevention and treatment of venous thromboembolism (VTE)
• Prophylaxis of deep‑vein thrombosis (DVT) after surgery or immobilization
• Prevention of clot formation in extracorporeal circuits such as dialysis or cardiopulmonary bypass
• Management of acute coronary syndromes where rapid anticoagulation is needed
• Use during cardiac catheterisation procedures to reduce procedural thrombosis risk

Heparin Léčiva may be associated with a range of adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common

• Minor bleeding at injection sites
• Bruising or hematoma formation
• Nausea or mild gastrointestinal discomfort
• Transient elevation of liver enzymes
• Mild thrombocytopenia (platelet count decrease)
• Localised redness or irritation

Serious

• Major hemorrhage, including intracranial or gastrointestinal bleeding
• Heparin‑induced thrombocytopenia (HIT) with paradoxical clot formation
• Severe allergic reactions such as anaphylaxis
• Spontaneous spinal or epidural hematoma
• Acute renal impairment in rare cases

Before initiating Heparin Léčiva, clinicians should evaluate patient‑specific factors and monitor for potential complications. Key precautions include:

• Assess baseline coagulation parameters (aPTT, platelet count) and repeat monitoring during therapy
• Use cautiously in patients with a history of bleeding disorders or recent major surgery
• Avoid in individuals with known hypersensitivity to heparin or pork products
• Consider dose adjustment in renal or hepatic impairment
• Counsel pregnant or lactating patients only under specialist guidance
• Ensure appropriate reversal agents (protamine sulfate) are available for emergency bleeding control

Heparin Léčiva can interact with several medications, influencing its anticoagulant effect or increasing bleeding risk.

Avoid

• Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) without specialist oversight
• High‑dose aspirin or non‑steroidal anti‑inflammatory drugs (NSAIDs) that potentiate bleeding
• Thrombolytic agents such as alteplase or streptokinase

Use with caution

• Antiplatelet agents (clopidogrel, ticagrelor) where combined effect may be additive
• Selective serotonin reuptake inhibitors (SSRIs) that can impair platelet function
• Glycoprotein IIb/IIIa inhibitors used in interventional cardiology
• Certain antibiotics (e.g., vancomycin) that may alter platelet counts